Title: Bioequivalence of Two Lansoprazole Delayed Release Capsules 30 mg in Healthy Male Volunteers under Fasting, Fed and Fasting-applesauce conditions: A Partial Replicate Crossover Study Design to Estimate the Pharmacokinetics of Highly Variable Drugs
Abstract: An open-label, 2-treatment, 3-sequence, 3-period, single-dose, partial replicate crossover studies under fasting (<i>n</i>=48), fed (<i>n</i>=60) and fasting-applesauce (<i>n</i>=48) (sprinkled on one table spoonful of applesauce) modalities were conducted in healthy adult male volunteers to evaluate bioequivalence between 2 formulations of lansoprazole delayed release capsules 30 mg. In all the 3 studies, as per randomization, either test or reference formulations were administered in a crossover manner with a required washout period of at least 7 days. Blood samples were collected adequately (0–24 h) to determine lansoprazole plasma concentrations using a validated LC-MS/MS analytical method. To characterize the pharmacokinetic parameters (C<sub>max</sub>, AUC<sub>0–t</sub>, AUC<sub>0–∞</sub>, T<sub>max</sub>, K<sub>el</sub> and T<sub>1/2</sub>) of lansoprazole, non-compartmental analysis and ANOVA was applied on ln-transformed values. The bioequivalence was tested based on within-subject variability of the reference formulation. In fasting and fed studies (within-subject variability>30%) bioequivalence was evaluated with scaled average bioequivalence, hence for the pharmacokinetic parameters C<sub>max</sub>, AUC<sub>0–t</sub> and AUC<sub>0–∞</sub>, the 95% upper confidence bound for (μT−μR)<sup>2</sup>−θσ<sup>2</sup> <sub>WR</sub> was ≤0, and the point estimates (test-to-reference ratio) were within the regulatory acceptance limit 80.00–125.00%. In fasting-applesauce study (within-subject variability<30%) bioequivalence was evaluated with average bioequivalence, the 90% CI of ln-transformed data of C<sub>max</sub>, AUC<sub>0–t</sub> and AUC<sub>0–∞</sub> were within the regulatory acceptance limit 80.00–125.00%. Based on these aforesaid statistical inferences, it was concluded that the test formulation is bioequivalent to reference formulation.
Publication Year: 2013
Publication Date: 2013-06-18
Language: en
Type: article
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 2
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot